Biohaven's Zavegepant Pain Spray Aces Late-Stage Migraine Trial

Biohaven Pharmaceutical Holding Company Ltd BHVN is eyeing filing for approval in early 2022 for its experimental pain spray after new data showed it hit its primary endpoints in a Phase 3 trial.

• The drug, zavegepant, a small-molecule CGRP receptor that can work as a spray and an oral med, showed "ultra-rapid pain relief" at the earliest measured time point of 15 minutes and sustained efficacy through 48 hours after a single intranasal dose in acute migraine.
• It hit its co-primary endpoints, namely pain freedom and freedom from "most bothersome" symptoms at two hours.
• It also showed "broad efficacy" after showing statistically significant superiority to placebo across a total of 15 prespecified primary and secondary outcome measures.
• The nearly 1,500-patient study found the drug was generally clean on safety, with most adverse events mild in intensity.
• It will hope to nab another FDA migraine approval after getting a recent green light for Nurtec for acute migraine earlier in the year.
• Read Next: Pfizer Gains Outside US Rights To Biohaven's Migraine Treatment For $500M.
• Alongside the data, the company announced Vlad Coric would also take on the chairman of the board position. It hired a new chief financial officer Matthew Buten, a former managing director of Foresite Capital.
• The move comes after the former chair of Declan Doogan, and CFO James Engelhart announced they were retiring from their positions.
• Price Action: BHVN shares are down 3.58% at $99.85 during the market session on the last check Monday.